Autopsy report · NCT03759184
Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia
Cause of deathSlow enrollment
“The study was closed after \> 1 year of inactivity.”
Life of this trial
- Registered 7 months before it started.
- Ran for about 2 years 3 months before it stopped.
- 1 participant enrolled.
- Results were posted on the registry 5 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1
- Sponsor
- National Cancer Institute (NCI)
- Sponsor type
- US National Institutes of Health
- Conditions
- Leukemia; Lymphocytic; Chronic; B-Cell
- Interventions
- rhIL-15; rhIL-15; Obinutuzumab
- Participants
- 1
- Sites
- 1
- Countries
- United States
Trials that died the same way
- Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies
“accrual was slow and sporadic so the study was closed” - A Supportive Care Intervention for Older Caregivers of Older Adults with Advanced Cancer
“Study has been closed to accrual earlier than anticipated and will not resume.” - Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia
“The study was closed due to the end of funding.” - A Comparison of Surgical Preparations and Wound Infection Rates for Elective Cesarean Sections
“Study was stopped following interim analysis.” - Assessment of Pulmonary Congestion During Cardiac Hemodynamic Stress Testing
“Study was stopped due to funding and time constraints.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.